Research advance on difference of efficacy and prognosis of tyrosine kinase inhibitor treatment for advanced non-small cell lung cancer patients with 19del and L858R mutation / 中国医师杂志

ABSTRACT

The epidermal growth factor receptor (EGFR) exon 19 deletion (19del) and the L858R point mutation of exon 21 are the most common types of EGFR mutations in non-small cell lung cancer (NSCLC).Treatment with EGFR tyrosine kinase inhibitors (TKI) can provide better survival benefit for some patients with advanced NSCLC.Clinical studies have shown that patients with these two types of mutations have different benefits in EGFR-TKI therapy.However,most patients treated with EGFR-TKI develop resistance after 12 months of treatment,the most common of which is the EGFR gene T790M mutation.In order to study the mechanism of resistance to TKI in NSCLC patients,and to develop new therapeutic methods and rational treatment strategies,further research on tumor characteristics in the whole disease progression and treatment process is indispensable.Exploring and comparing the differences between 19del and L858R and T790M in obtaining resistance to TKI is of great clinical significance.